PsychoGenics – Phenotypic Drug Discovery and Preclinical CRO
Mark Varney, Ph.D., Chief Scientific Officer of PsychoGenics, an AI-enabled phenotypic drug discovery and preclinical contract research organization (CR...
57 articles
Mark Varney, Ph.D., Chief Scientific Officer of PsychoGenics, an AI-enabled phenotypic drug discovery and preclinical contract research organization (CR...
Returning guest, Lloyd Miller, MD, PhD, Vice President, Immunodermatology Disease Area Leader for the Immunology Therapeutic Area at Janssen Research & ...
Priya Kishnani, MD, Chen Family Professor of Pediatrics, Chief of the Division of Medical Genetics at Duke University Medical Center and Medical Directo...
Jeff Bova, Chief Commercial Officer at UroGen Pharma discusses the launch of their first FDA-approved treatment, the only non-surgical option for patien...
Lloyd Miller, MD, PhD, Vice President, Immunodermatology Disease Area Leader at Janssen, discusses new data presented at the 2021 European Academy of De...
Dave Craig, two-time cancer survivor, co-founder and CEO of GRYT Health, a digital oncology company that empowers people to be in charge of their own he...
Moderate to severe fatigue affects nearly 50% of psoriatic arthritis (PsA) patients and greatly impacts their quality of life. Dr.
Jared Silver, MD, PhD, Allergist Immunologist & Indication Lead for Mepolizumab, US Medical Affairs Respiratory at GSK discusses the recent FDA approval...
Most people who suffer a stroke aren’t treated in time to prevent long-term and often permanent effects on speech, cognition and motor function.
John Orwin, President and CEO of Atreca, a biopharmaceutical company, discusses their drug Discovery Platform and how they are thinking differently abou...